NO960551L - Antibody based treatment of HIV infection - Google Patents

Antibody based treatment of HIV infection

Info

Publication number
NO960551L
NO960551L NO960551A NO960551A NO960551L NO 960551 L NO960551 L NO 960551L NO 960551 A NO960551 A NO 960551A NO 960551 A NO960551 A NO 960551A NO 960551 L NO960551 L NO 960551L
Authority
NO
Norway
Prior art keywords
hiv
complexes
antibody
complement
antigen
Prior art date
Application number
NO960551A
Other languages
Norwegian (no)
Other versions
NO960551D0 (en
Inventor
Robert B Naso
Original Assignee
Univax Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univax Biolog Inc filed Critical Univax Biolog Inc
Publication of NO960551L publication Critical patent/NO960551L/en
Publication of NO960551D0 publication Critical patent/NO960551D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En metode for å redusere eller forhindre progressjonen av HIV infeksjon i et HIV-eksponert individ, og forhindre HIV-infeksjon i et individ som har en risiko for HIV-. i. infeksjon, omfatter tilveiebringing av antistoffantigen kompleks eller. antistoff:antigen:komplementkompleks til individet i titere som er tilstrekkelig for på konkurrerende måte å inhibere HIV-komplekscr fra og binde celler via Fc reseptorer eller komplementreseptorer i lymfoid vev. Denne metoden anvender antistoffer som blir bundet til cellulære antigener for å danne antigen:antistoff komplekser og/eller antigen:antistoff:komplementkomplekser, som igjen inhiberer eller forhindrer bindingen av HIV:antistoff komplekser eller HIV:antistoff:komplementkomplekser eller HIV:komplementkomplekser til cellene i lymfoid vev. Ved å hemme konsentrasjonen. i av HIV komplekser bundet til lymfevev reduseres belastningen av viralt infiserte celler. og øker effektiviteten til anti-retrovirale midler og øker virus inaktiveringen i blodstrømmen. Den reduserte konsentrasjonen eller fraværet av HIV i lymfevev hindrer infeksjon av CD4+ T celler deri.A method for reducing or preventing the progression of HIV infection in an HIV-exposed individual, and preventing HIV infection in an individual at risk for HIV infection, comprises providing antibody antigen complex or antibody:antigen:complement complex to the individual in titers sufficient to competitively inhibit HIV complexes from and bind cells via Fc receptors or complement receptors in lymphoid tissues. This method utilizes antibodies that bind to cellular antigens to form antigen:antibody complexes and/or antigen:antibody:complement complexes, which in turn inhibit or prevent the binding of HIV:antibody complexes or HIV:antibody:complement complexes or HIV:complement complexes to the cells in lymphoid tissues. By inhibiting the concentration of HIV complexes bound to lymphoid tissues, the burden of virally infected cells is reduced, and the effectiveness of anti-retroviral agents is increased, and virus inactivation in the bloodstream is increased. The reduced concentration or absence of HIV in lymphoid tissue prevents infection of CD4+ T cells therein.

NO960551A 1993-08-13 1996-02-12 Antibody based treatment of HIV infection NO960551D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10558493A 1993-08-13 1993-08-13
PCT/US1994/008312 WO1995005196A1 (en) 1993-08-13 1994-08-10 Antibody-based treatment of hiv infection

Publications (2)

Publication Number Publication Date
NO960551L true NO960551L (en) 1996-02-12
NO960551D0 NO960551D0 (en) 1996-02-12

Family

ID=22306655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960551A NO960551D0 (en) 1993-08-13 1996-02-12 Antibody based treatment of HIV infection

Country Status (5)

Country Link
EP (1) EP0715522A1 (en)
AU (1) AU703324B2 (en)
CA (1) CA2169370A1 (en)
NO (1) NO960551D0 (en)
WO (1) WO1995005196A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993812A (en) * 1995-09-14 1999-11-30 Cangene Corporation Method of delaying the progression of an infection with the human immunodeficiency virus
CA2637707A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1168152A (en) 1981-10-20 1984-05-29 Winnipeg Rh Institute Inc. (The) Process for preparing human plasma fractions containing immune globulin (igg)
WO1991006575A1 (en) * 1989-11-03 1991-05-16 Repligen Corporation Hiv-1 specific human monoclonal antibody

Also Published As

Publication number Publication date
AU7550494A (en) 1995-03-14
WO1995005196A1 (en) 1995-02-23
CA2169370A1 (en) 1995-02-23
AU703324B2 (en) 1999-03-25
EP0715522A1 (en) 1996-06-12
NO960551D0 (en) 1996-02-12

Similar Documents

Publication Publication Date Title
Nara et al. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses
Schols et al. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1
Kohler et al. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination
Daar et al. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
Pahwa et al. Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.
Mascola Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1
Li et al. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins
Schmitz et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.
JPH06502539A (en) Neutralizing human monoclonal antibody specific for the V3 loop and CD-4 binding site of HIV-1 GP120
NZ334941A (en) Methods for treating infections using proteins which induce an immune response in one animal species but not in another
Burkly et al. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies
EP1003552A4 (en) LO-CD2a ANTIBODIES AND THEIR USE FOR INHIBITING T-CELL ACTIVATION AND GROWTH
Oxenius et al. Variable fate of virus‐specific CD4+ T cells during primary HIV‐1 infection
Carpenter et al. Recent insights into Fc-mediated effector responses to HIV-1
Castro et al. HIV-1 expression in chimpanzees can be activated by CD8+ cell depletion or CMV infection
Kennedy et al. Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope.
Burrer et al. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig) G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41
ATE335835T1 (en) ANTIBODIES AGAINST A COMPLEX OF CD4 AND A CHEMOKINE RECEPTOR DOMAIN, AND THEIR USE AGAINST HIV INFECTIONS
Bretscher et al. Vaccination against and treatment of tuberculosis, the leishmaniases and AIDS: perspectives from basic immunology and immunity to chronic intracellular infections
Tanabe-Tochikura et al. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro
Sanhadji et al. Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice
Galéa et al. Rationale for a vaccine using cellular-derived epitope presented by HIV isolates
Ahmed et al. Role of CD8+ cell‐produced anti‐viral factors in protective immunity in HIV‐2‐exposed but seronegative macaques resistant to intrarectal SIVsm challenge
Daniel et al. Sequential occurrence of IgM, IgM/IgG, and gp120-IgM/IgG complement complexes on CD4+ lymphocytes in relation to CD4+ blood lymphocyte depletion in HIV+ hemophilia patients: results of a 10-year study
Lecoq et al. Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy